JPRN-UMIN000014661招募中2 期
Phase II study of dose-escalation of Regorafenib for patients with previously treated metastatic colorectal cancer. - DEREGULATE study
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients with synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ. 2. Case with the history of usage of the Regorafenib. 3. Case with the history of usage of the TAS-102. 4. Patients with uncontrolled hypertension. 5. Patients suffering watery stools or diarrhea. 6. Patients who have gastrointestinal perforation or bleeding. 7. Patients with non-healing wound (excluding central venous reservoir). 8. Patients with infectious disease and febrile condition (over 38 centigrade). 9. Patients who have active hepatitis type B or C. 10. Patients with chronic heart failure of NYHA Class 2 or worse. 11. Patients with history of cardiovascular events including unstable angina, cardiac infarction, cerebral infarction and pulmonary embolism within 6 months. 12. Patients with ileus or severe intestinal obstruction. 13. Patients with disorders of the central nervous system. 14. Patients with a history of the severe hypersensitivity to regorafenib. 15. Pregnant or lactating woman. 16. Other patients who are unfit for the study as determined by the attending physician.
研究者
相似试验
已完成
不适用
Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer who are progressed after standard chemotherapyJPRN-UMIN000018968Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group60
尚未招募
不适用
First-line reogorafenib-nivolumab combination for advanced hepatocellular carcinomaNeoplasmsKCT0004867Asan Medical Center42
进行中（未招募）
1 期
Regorafenib as a single agent for treatment of patients with metastatic colorectal cancer (MCRC) who are not candidates for polychemotherapyEUCTR2013-000236-94-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)
进行中（未招募）
1 期
A phase II trial of neoadjuvant REGorafenib in combination with nIvolumab and short-course radiotherapy iN stage II-III rectAl cancerrectal cancerMedDRA version: 21.0Level: PTClassification code 10038049Term: Rectal cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10038050Term: Rectal cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000876-40-BEInstitut Jules Bordet90
进行中（未招募）
1 期
Study of Regorafenib drug for the treatment of patients with metastatic colorectal cancer (mCRC) with any RAS or BRAF gen mutation previously treated with FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) plus bevacizumabmetastatic colorectal cancerMedDRA version: 16.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2014-000703-26-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)